Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 3
1975 25
1976 45
1977 57
1978 82
1979 127
1980 130
1981 172
1982 212
1983 220
1984 260
1985 230
1986 198
1987 208
1988 215
1989 211
1990 216
1991 178
1992 142
1993 159
1994 159
1995 147
1996 120
1997 140
1998 140
1999 157
2000 193
2001 162
2002 155
2003 215
2004 182
2005 213
2006 240
2007 243
2008 225
2009 242
2010 222
2011 224
2012 262
2013 261
2014 322
2015 281
2016 272
2017 238
2018 248
2019 265
2020 281
2021 199
Text availability
Article attribute
Article type
Publication date

Search Results

8,562 results
Results by year
Filters applied: . Clear all
Page 1
Metoprolol succinate combination in the treatment of hypertension.
Papadopoulos DP, Papademetriou V. Papadopoulos DP, et al. Angiology. 2009 Oct-Nov;60(5):608-13. doi: 10.1177/0003319708326450. Epub 2008 Nov 24. Angiology. 2009. PMID: 19033265 Review.
Metoprolol is a selective beta(1)-adrenergic antagonist extensively used since 1975. ...A 100-mg metoprolol controlled/extended-release tablet contains 95 mg of metoprolol succinate and is considered to have equivalent activity of 100 mg metoprolol tar
Metoprolol is a selective beta(1)-adrenergic antagonist extensively used since 1975. ...A 100-mg metoprolol controlled/extende
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.
POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. POISE Study Group, et al. Lancet. 2008 May 31;371(9627):1839-47. doi: 10.1016/S0140-6736(08)60601-7. Epub 2008 May 12. Lancet. 2008. PMID: 18479744 Free article. Clinical Trial.
More patients in the metoprolol group than in the placebo group had a stroke (41 [1.0%] vs 19 [0.5%] patients; 2.17, 1.26-3.74; p=0.0053). ...Patients are unlikely to accept the risks associated with perioperative extended-release metoprolol....
More patients in the metoprolol group than in the placebo group had a stroke (41 [1.0%] vs 19 [0.5%] patients; 2.17, 1.26-3.74; p=0.0 …
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Jánosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Hjalmarson A, et al. JAMA. 2000 Mar 8;283(10):1295-302. doi: 10.1001/jama.283.10.1295. JAMA. 2000. PMID: 10714728 Clinical Trial.
OBJECTIVE: To examine the effects of the beta1-blocker controlled-release/extended-release metoprolol succinate (metoprolol CR/XL) on mortality, hospitalization, symptoms, and quality of life in patients with heart failure. ...NYHA functional class, assessed by phys …
OBJECTIVE: To examine the effects of the beta1-blocker controlled-release/extended-release metoprolol succinate (metoprolol CR …
The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine.
Bahar MA, Kamp J, Borgsteede SD, Hak E, Wilffert B. Bahar MA, et al. Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715. doi: 10.1111/bcp.13741. Epub 2018 Sep 24. Br J Clin Pharmacol. 2018. PMID: 30248178 Free PMC article.
A cohort study indicated that the DDI was significantly associated with the incidence of early discontinuation of metoprolol as an indicator of the emergence of metoprolol-related side effects. ...Nonetheless, if prescribing the combination is unavoidable, a dose ad …
A cohort study indicated that the DDI was significantly associated with the incidence of early discontinuation of metoprolol as an in …
S-metoprolol: the 2008 clinical review.
Dasbiswas A, Shinde S, Dasbiswas D. Dasbiswas A, et al. J Indian Med Assoc. 2008 Apr;106(4):259-62. J Indian Med Assoc. 2008. PMID: 18828349 Review.
This confirms higher cardioselectivity of S-metoprolol in clinical settings. Less interaction potential of S-metoprolol compared to R-isomer further makes it a sensible choice in patients taking CYP2D6 inhibitors or in patients with heart failure or hepatic insuffic …
This confirms higher cardioselectivity of S-metoprolol in clinical settings. Less interaction potential of S-metoprolol compar …
Rediscovering Chirality - Role of S-Metoprolol in Cardiovascular Disease Management.
Mohan JC, Shah SN, Chinchansurkar S, Dey A, Jain R. Mohan JC, et al. J Assoc Physicians India. 2017 Jun;65(6):74-79Jagdish. J Assoc Physicians India. 2017. PMID: 28782316 Review.
METHODS: Relevant articles from Pubmed, Embase, Medline and Google Scholar were searched using the terms "Chiral", "Chirality", "Enantiomers", "Isomers", "Isomerism", "Stereo-chemistry", and "S-Metoprolol". Out of 103 articles found 17 articles mentioning in general about …
METHODS: Relevant articles from Pubmed, Embase, Medline and Google Scholar were searched using the terms "Chiral", "Chirality", "Enantiomers …
Extended-release metoprolol succinate in chronic heart failure.
Tangeman HJ, Patterson JH. Tangeman HJ, et al. Ann Pharmacother. 2003 May;37(5):701-10. doi: 10.1345/aph.1C286. Ann Pharmacother. 2003. PMID: 12708950 Review.
DATA SOURCES: A MEDLINE search of English-language literature (1990-October 2002) was conducted using congestive heart failure and metoprolol CR/XL or metoprolol CR/ZOK as search terms to identify pertinent studies. STUDY SELECTION/DATA EXTRACTION: All of the articl …
DATA SOURCES: A MEDLINE search of English-language literature (1990-October 2002) was conducted using congestive heart failure and metopr
[Metoprolol CR/XL: advanced formulation of a classical beta-blocker].
Kobalava ZhD, Gudkov KM. Kobalava ZhD, et al. Kardiologiia. 2003;43(9):91-100. Kardiologiia. 2003. PMID: 14593374 Review. Russian.
Metoprolol is a selective beta(1)-adrenergic antagonist extensively used in major fields of cardiology since 1975. ...More recently evidence for antiatherogenic activity of metoprolol succinate has been also obtained....
Metoprolol is a selective beta(1)-adrenergic antagonist extensively used in major fields of cardiology since 1975. ...More recently e
Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
Talbert RL. Talbert RL. Heart Fail Rev. 2004 Apr;9(2):131-7. doi: 10.1023/B:HREV.0000046368.08825.20. Heart Fail Rev. 2004. PMID: 15516861 Review.
Metoprolol tartrate is a short-acting form of metoprolol while metoprolol succinate is a longer acting salt and the commercially available product is designed as a once daily formulation. A recently published trial, the Carvedilol or Metoprolol Europea
Metoprolol tartrate is a short-acting form of metoprolol while metoprolol succinate is a longer acting salt and the com
Metoprolol: a review of its use in chronic heart failure.
Prakash A, Markham A. Prakash A, et al. Drugs. 2000 Sep;60(3):647-78. doi: 10.2165/00003495-200060030-00011. Drugs. 2000. PMID: 11030472 Review.
The incidence of sudden death and death due to progressive heart failure were both significantly decreased with metoprolol CR/XL. Similarly, a trend towards decreased mortality in the metoprolol CR/XL group compared with placebo was observed in the RESOLVD trial. .. …
The incidence of sudden death and death due to progressive heart failure were both significantly decreased with metoprolol CR/XL. Sim …
8,562 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page